Clinical Trial Update: Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating iloprost inhaled solution as add-on therapy to bosentan in patients with pulmonary arterial hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ayerza Syndrome
• Pulmonary Arterial Hypertension
• Pulmonary Hypertension

Drugs mentioned

• TRACLEER (bosentan)
• Ventavis (iloprost)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension, Ayerza Syndrome | Phase 2 | Status: COMPLETED